Meta-analysis of the Efficacy and Safety of Benazepril vs. Captopril in the Treatment of Primary Hypertension
10.6039/j.issn.1001-0408.2015.18.26
- VernacularTitle:贝那普利对比卡托普利治疗原发性高血压疗效与安全性的Meta分析
- Author:
Su ZHAO
;
Wanhua YANG
;
Bing CHEN
- Publication Type:Journal Article
- Keywords:
Primary hypertension;
Benazepril;
Captopril;
Systematic review;
Meta-analysis;
Efficacy;
Safety
- From:
China Pharmacy
2015;(18):2524-2526
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically analyze the efficacy and safety of benazepril vs. captopril in the treatment of prima-ry hypertension and provide evidence-based reference for the clinical treatment. METHODS:Cochrane Library,PubMed,EM-Base,CJFD,VIP database and Wanfang database were retrieved to collect the randomized controlled trials (RCT) of benazepril (experiment group)vs. captopril(control group)in the treatment of primary hypertension. After information collection and quality evaluation,Meta-analysis was conducted by using Rev Man 5.0 software. RESULTS:Totally 7 RCTs involving 405 patients were in-cluded. The results of Meta-analysis showed that the level of systolic blood pressure(SBP)[MD=-2.06,95%CI(-3.75,-0.38), P=0.02] and diastolic blood pressure(DBP)[MD=-3.10,95%CI(-5.19,-1.01),P=0.004] in experiment group was sig-nificantly lower than control group;however,there were no significant differences between the efficacy rate of antihypertension [OR=1.63,95%CI(0.69,3.83),P=0.26] and incidence of adverse drug reactions(ADR)[OR=0.81,95%CI(0.46,1.41),P=0.45] in 2 groups. CONCLUSIONS:Benazepril can more effectively lower the blood pressure of patients with primary hypertension than captopril. Due to the limitation of methodology quality,it remains to be further verified by high-quality and large-sample RCT.
